Blog

Earlier this summer, the Rare Genomics Institute announced the winners of the 2018 BeHEARD (Help Empower & Accelerate Research Discoveries) Challenge. The Challenge tasks researchers or foundations working in fields of rare disease research to apply for grants, either financial or technological, to assist their research. We caught up with the Institute’s Arvin M. Gouw to discuss the awards and the battle against rare disease.

Degenerative disc diseases are debilitating, and treatment options are lacking. Three leaders from Discgenics explain how they are harnessing the restorative potential of cells native to the intervertebral disc to alleviate lower back pain.

The failure of conventional antibiotics to treat numerous antibiotic-resistant infections necessitates the development of new agents – as a natural anti-microbial nitric oxide holds particular promise.

In early July, experts from around the world met in Nice, France, to share and discuss the latest innovations and research in the context of human lung in vitro models. This blog highlights some of the topics covered during the event.

Following the recent FDA approval of a procalcitonin assay, we spoke with a representative from Fujirebio Diagnostics, Inc. to learn how measuring this important biomarker will improve the healthcare landscape.

In February 2018, a team at Rady Children's Institute for Genomic Medicine broke the world record for the fastest genetic diagnosis when they delivered a rare disease diagnosis in just 19 hours 30 minutes. We caught up with John Reynders, CEO of Alexion, to discuss how the record was broken, and why diagnosing rare diseases is important in modern medicine.

Science advances at a rapid pace, and supporting technologies and infrastructures have to adapt accordingly. One of the latest evolutions in technology is the shift from traditional software and hardware tools to newer cloud-based services. In this blog, Thermo Fisher Scientific's Karen Velardi looks at, we look at the different cloud services that are changing the way modern research is done.

In the second of a two-part blog series, we talk with Genestack CEO Misha Kapushesky on the developments in Bioinformatics that he’s most excited about, and the latest modular additions to Genestack's bioinformatics platform.